[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100651614","sarcopenia-in-acute-ischemic-stroke-100651614",false,"NCT07764172","Sarcopenia in Acute Ischemic Stroke","Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes","Inclusion Criteria:\n\n* Age 50 years and older\n* Acute ischemic stroke confirmed by CT or MRI\n* Admission within the first 72 hours\n* Written informed consent and availability of a contact telephone number for follow-up\n\nExclusion Criteria:\n\n* TIA without a visible lesion on neuroimaging; bilateral hemiparesis\n* Amputations or severe contractures that preclude anthropometric assessment\n* Active cancer at stage IV or life expectancy of less than 3 months\n* Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months\n* Pregnancy; refusal to participate\n\nDiscontinuation criteria (drop-out)\n\n* Discharge or death within the first 7 days\n* Withdrawal of consent\n* Transfer to another facility resulting in loss of contact","ALL","50 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is:\n\nIs the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality?\n\nParticipants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.",[24,25],"Sarcopenia","Acute Stroke",[27,28],"sarcopenia","acute stroke","RECRUITING","2026-08-12",{"date":32,"type":33},"2026-08-13","ACTUAL",{"date":35,"type":20},"2026-08",{"date":37,"type":20},"2029-12-31",{"name":39,"class":40},"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100582983","phase-3-bacteriophages-in-addition-to-antibiotics-for-the-treatment-of-patients-with-infective-endocarditis-100582983","NCT06870409","Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis","A Prospective Interventional Randomized Placebo-controlled Multicenter Clinical Trial of the Efficacy, Tolerability and Safety of Phage Therapy in Combination With Standard Antibiotic Therapy in Patients With Infective Endocarditis","PHARAOH","Inclusion Criteria:\n\n* Hospitalisation with active IE or active IE developed in hospital;\n* Definite diagnosis of IE according to modified Duke 2023 criteria or possible diagnosis of IE but managed and treated as IE;\n* Informed consent to participate in the study;\n\nExclusion Criteria:\n\n* Inactive (transferred) IE\n* Non-bacterial thrombotic endocarditis\n* Active oncological diseases\n* Immunosuppressive therapy","18 Years",{"count":52,"type":20},30,"INTERVENTIONAL",[55],"PHASE3","Infective endocarditis (IE) is an endocardial lesion caused by bacterial and\u002For fungal infection that most commonly affects the heart valves and\u002For the endocardium around implanted intracardiac devices. In general, IE is classified as a rare disease, but there has been a steady increase in incidence, primarily in high-income countries. The danger of IE lies in the high frequency of complicated course of the disease and the risk of lethal outcomes both at the inpatient stage of treatment 25.0% and in the distant period 30-40%. The annual incidence is from 3 to 10 per 100,000 people.\n\nIn addition to the difficulties in the diagnosis of IE, the most challenging aspect is the prescription of effective antibiotic therapy, especially in the context of unidentified etiology of IE and the growth of multi-resistant pathogens. Many solutions are used to achieve successful therapy of IE, including the prescription of combined antibiotic therapy, the use of new modern antibacterial drugs, the prescription of therapy taking into account the sensitivity of the pathogen, but the failure of treatment and the number of resistant pathogens are only increasing. Moreover, antibacterial therapy is relevant both in patients on conservative treatment of IE and after cardiac surgery, among whom the risk of nosocomial or healthcare-associated infections is additionally increased. Thus, new ways of modernising IE therapy are needed. Phage therapy is considered one of the promising strategies \\[6-8\\]. Bacteriophages are certain viruses that naturally infect bacteria and are used as antibacterial treatments. Phagotherapy is used as antibacterial drugs that can induce lysis of target pathogens.",[58],"Endocarditis, Bacterial",[60,61],"infective endocarditis","bacteriophages","2026-03-17",{"date":64,"type":33},"2026-03-19",{"date":66,"type":33},"2025-02-05",{"date":68,"type":20},"2029-02-05",{"name":39,"class":40},""]